Clinical Trial Update: Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating exogenous testosterone plus dutasteride for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DUTASTERIDE (Dutasteride)
• TESTOSTERONE (testosterone)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer, Castration-resistant, Metastatic | Phase 2 | Status: COMPLETED